The next step will be to investigate the ability of continuous APOA4 infusion to attenuate potential obesity-related complications through the elevation of BAT thermogenesis and downregulation of hypertriglyceridemia in the face of a HFD challenge. The gene discussed is APOA4; the disease is obesity due to melanocortin 4 receptor deficiency.